Hazelden Betty Ford Recognized by Newsweek's "America's Best Addiction Treatment Centers 2025"
California and Newberg, Oregon--(Newsfile Corp. - October 8, 2025) - Hazelden Betty Ford has again been recognized by Newsweek's America's Best Addiction Treatment Centers in 2025, and is the largest, most frequently named national nonprofit provider on the 2025 listings. The annual rankings name the top treatment centers nationwide by state, based on quality of care, accreditation, reputation, and patient experience. The Hazelden Betty For
2025-10-08 9:00 AM EDT | Hazelden Betty Ford Foundation
Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%
Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia Nut
Healthcare and Hospitals, Health
2025-10-08 8:30 AM EDT | Adia Nutrition Inc.
Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement. The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit.
Biotechnology, Pharmaceuticals, Health
2025-10-07 5:48 PM EDT | Genix Pharmaceuticals Corp.
Hemostemix's Insider Lead Order of $330,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000. Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date, subje
Biotechnology, Pharmaceuticals, Health
2025-10-07 10:05 AM EDT | Hemostemix Inc.
Hear At Last Launches Token on Solana Blockchain to Raise $10 Million for Portable Homes in Jamaica and North America
Miami, Florida--(Newsfile Corp. - October 7, 2025) - Hear At Last (OTCID: HRAL), a leader in innovative housing solutions, is proud to announce the creation of a new cryptocurrency token, HOHM, on the Solana blockchain. This initiative is aimed at raising $10 million to support the development and distribution of portable homes in Jamaica and North America. The HOHM token represents a groundbreaking step in combining blockchain technology with sustainable housing projects. By lev
Household / Consumer / Cosmetics, Health
2025-10-07 8:00 AM EDT | Hear AtLast Holdings, Inc
Edison Issues Report on Percheron Therapeutics (PER)
London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER) Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the compound's favourable safety and tolerability profile (maximum tolerated dose not reached with <10% of patients experiencing grade 3 or greater adverse events), with e
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-10-07 4:38 AM EDT | Edison Group
Cosmo Pharmaceuticals Announces Regulatory Approval of Winlevi(R) in South Korea
Dublin, Ireland--(Newsfile Corp. - October 7, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This approval marks another important milestone in Cosmo’s global dermatology expansion and r
Healthcare and Hospitals, Health
2025-10-07 1:09 AM EDT | Cosmo Pharmaceuticals N.V.
LevelJump Announces Reinstatement of Trading on the TSX Venture Exchange and Provides Corporate Updates
Toronto, Ontario--(Newsfile Corp. - October 6, 2025) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce that, further to its press release of June 24, 2025, trading on the TSX Venture Exchange (the "Exchange") will resume with trading expected to be reinstated on or about October 9, 2025. Disclosure relating to the Company's activities during the past 12 months (including an annual information form) is readily av
Healthcare and Hospitals, Health
2025-10-06 6:45 PM EDT | LevelJump Healthcare Corp.
Adia Nutrition Inc. Divests Biolete Coffee Subsidiary to Cement Factory LLC, Retains 18% Ownership to Support Strategic Focus on Regenerative Medicine and Medical Sales
Winter Park, Florida--(Newsfile Corp. - October 6, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine and innovative healthcare solutions, today announced the sale of its Biolete coffee subsidiary to Cement Factory LLC, a dynamic consumer products firm led by key owners Jeff Sciullo and AJ Sims. Adia will retain an 18% ownership stake in Cement Factory LLC, ensuring continued alignment with Biolete's growth while enabling Adia to concentrate resources on it
Healthcare and Hospitals, Health
2025-10-06 12:39 PM EDT | Adia Nutrition Inc.
Healing Realty Trust Acquires Highland Park Medical Office Building, a Fully Leased Healthcare Property in Highland Park, Illinois
Jupiter, Florida--(Newsfile Corp. - October 6, 2025) - Healing Realty Trust Inc. ("Healing Realty Trust," "HRT" or the "Company"), a healthcare-focused real estate investment company concentrated on acquiring value-add to core-plus medical office buildings with core-like, durable cash flows, is pleased to announce the acquisition of a single-story, multi-tenant medical office property located at 1160 Park Avenue West in Highland Park, Illinois. The asset was acquired for $4,915,000, represent
Banking / Financial Services, Real Estate, Health
2025-10-06 9:42 AM EDT | Healing Realty Trust
Delivra Health Brands Reports Continued Revenue Growth and Positive Adjusted EBITDA(1) in FY2025
Dream Water® USA and Dream Water® Canada achieve double digit revenue growth in e-commerce and retail channels LivRelief™ Canada achieves double-digit revenue growth in ecommerce Strong Dream Water and LivRelief results partially offset by reduced revenues in LivRelief Infused business. Management implementing new route-to-market strategy to recapture growth
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2025-10-06 7:30 AM EDT | Delivra Health Brands Inc.
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder va
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-06 7:00 AM EDT | Cannabis Bioscience International Holdings
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-06 7:00 AM EDT | Optimi Health Corp.
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025. At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners acro
Biotechnology, Pharmaceuticals, Health
2025-10-06 3:15 AM EDT | Defence Therapeutics Inc.
MyndTec Inc. Completes Fifth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - October 2, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the fifth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The fifth tranche of the private placement consists of 522,106 Units of the Company (the "Un
Technology, Healthcare and Hospitals, Health
2025-10-02 6:00 PM EDT | MyndTec Inc.
Delivra Health Brands to Hold Conference Call to Discuss Results for the Year Ending June 30, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods leader uniquely positioned in the health and wellness sector, is pleased to announce it will report its annual financial results for the year ending June 30, 2025, on Monday, October 6, 2025. Conference Call Details The Company will host a conference call on Monday, Oct
Cannabis, Health, Cannabis Extractor, Cannabis Manufacturer
2025-10-02 5:15 PM EDT | Delivra Health Brands Inc.
Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - October 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), and consistent with prior quarters, the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on September 30, 2025 unde
2025-10-02 4:31 PM EDT | Rapid Dose Therapeutics Corp.
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building
Biotechnology, Pharmaceuticals, Health
2025-10-02 3:15 AM EDT | Defence Therapeutics Inc.
CardioComm Solutions Announces Royalty-Based Financing Deal
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announces that it has entered into a royalty-based financing arrangement (the "Royalty Agreement") with current debt lenders to the Company (the "Lenders") in order secure new capital required to complete and commercialize the Company'
Technology, Healthcare and Hospitals, Health
2025-10-01 11:55 PM EDT | CardioComm Solutions, Inc.
cbdMD, Inc. Announces Closing of $1.7 Million Series B Preferred Private Placement
Charlotte, North Carolina--(Newsfile Corp. - October 1, 2025) - cbdMD, Inc. (NYSE American: YCBD), a leading wellness company and the parent of Herbal Oasis THC seltzers, ATRx functional mushroom supplements, and Paw CBD, today announces that it has entered into a securities purchase agreement with institutional investors including C/M Capital Master Fund, LP (the "Investors") whereby Company issued the Investors a Series B Convertible Preferred Stock (the "Shares") in consideration of gross
Household / Consumer / Cosmetics, Sports, Cannabis, Health
2025-10-01 4:15 PM EDT | cbdMD